Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Talos Energy estimates Q2 average daily production 66,000M Boe/d » 07:12
07/26/21
07/26
07:12
07/26/21
07:12
TALO

Talos Energy

$10.92 /

-0.36 (-3.19%)

Talos Energy announced…

Talos Energy announced preliminary production estimates for the Q2 successful first production from the Company's Tornado Attic well and successful drilling of the Company's Crown and Anchor well. Talos estimates that average daily production for the Q2 was approximately 66,000 barrels of oil equivalent per day, or MBoe/d, net, ahead of Company expectations, and was approximately 69% oil and 76% liquids. Estimated realized prices for the quarter, exclusive of hedges, were $64.28/barrel of oil, $22.28/barrel of NGLs and $3.05/mcf of natural gas.Following successful drilling of the Tornado Attic well, announced in June 2021, Talos executed completion operations and achieved first production in mid-July 2021. The well is currently producing above the previously estimated 8-10 MBoe/d range. The Company also increased injection rates in the structurally downdip Tornado injector well and is now injecting at a rate of over 30,000 barrels of water per day into the producing B-6 formation. The project is the first intra-well water flood of its kind in a deepwater subsea environment and is intended to increase overall production and recovery efficiency through the existing subsea producing wells. Talos holds a 65% working interest along with Kosmos Energy.

ShowHide Related Items >><<
TALO Talos Energy
$10.92 /

-0.36 (-3.19%)

TALO Talos Energy
$10.92 /

-0.36 (-3.19%)

06/08/21
Fly Intel: Top five analyst initiations
06/08/21 Citi
Talos Energy initiated with a Buy at Citi
05/03/21 Roth Capital
Talos Energy price target raised to $18 from $13 at Roth Capital
04/13/21 Stifel
BP discovery holds over 100MMboe of potential net to Talos interest, says Stifel
TALO Talos Energy
$10.92 /

-0.36 (-3.19%)

  • 24
    Jun
  • 09
    Dec
TALO Talos Energy
$10.92 /

-0.36 (-3.19%)

TALO Talos Energy
$10.92 /

-0.36 (-3.19%)

Over a week ago
On The Fly
Fly Intel: After-Hours Movers » 18:28
07/19/21
07/19
18:28
07/19/21
18:28
CCK

Crown Holdings

$101.33 /

-2.47 (-2.38%)

, IBM

IBM

$138.13 /

-0.79 (-0.57%)

, AMRX

Amneal Pharmaceuticals

$4.32 /

+0.01 (+0.23%)

, ODT

Odonate Therapeutics

$3.48 /

+0.025 (+0.72%)

, RCUS

Arcus Biosciences

$29.59 /

+0.16 (+0.54%)

, SIRI

Sirius XM

$6.35 /

-0.03 (-0.47%)

, PPG

PPG

$165.52 /

-4.77 (-2.80%)

, STLD

Steel Dynamics

$58.06 /

-1.8 (-3.01%)

, ZION

Zions Bancorp

$47.69 /

-1.91 (-3.85%)

, JBHT

J.B. Hunt

$159.83 /

-5.205 (-3.15%)

, ARDX

Ardelyx

$7.70 /

+0.195 (+2.60%)

Check out this evening's…

ShowHide Related Items >><<
ZION Zions Bancorp
$47.69 /

-1.91 (-3.85%)

STLD Steel Dynamics
$58.06 /

-1.8 (-3.01%)

SIRI Sirius XM
$6.35 /

-0.03 (-0.47%)

RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

PPG PPG
$165.52 /

-4.77 (-2.80%)

ODT Odonate Therapeutics
$3.48 /

+0.025 (+0.72%)

JBHT J.B. Hunt
$159.83 /

-5.205 (-3.15%)

IBM IBM
$138.13 /

-0.79 (-0.57%)

CCK Crown Holdings
$101.33 /

-2.47 (-2.38%)

ARDX Ardelyx
$7.70 /

+0.195 (+2.60%)

AMRX Amneal Pharmaceuticals
$4.32 /

+0.01 (+0.23%)

CCK Crown Holdings
$101.33 /

-2.47 (-2.38%)

05/28/21 RBC Capital
Crown Holdings price target raised to $150 from $140 at RBC Capital
05/26/21
Fly Intel: Top five analyst downgrades
05/25/21 BMO Capital
Crown Holdings downgraded to Market Perform from Outperform at BMO Capital
05/25/21 Citi
Canpack U.S. plant news a negative for Ball and Crown, says Citi
IBM IBM
$138.13 /

-0.79 (-0.57%)

07/16/21 BMO Capital
IBM price target raised to $155 from $150 at BMO Capital
07/12/21 Summit Insights
UiPath initiated with a Sell at Summit Insights
04/20/21 Credit Suisse
IBM price target raised to $165 from $160 at Credit Suisse
04/20/21 Stifel
IBM price target raised to $151 from $147 at Stifel
AMRX Amneal Pharmaceuticals
$4.32 /

+0.01 (+0.23%)

04/14/21 Guggenheim
Amneal Pharmaceuticals price target raised to $8 from $6.50 at Guggenheim
04/06/21 RBC Capital
Amneal Pharmaceuticals transferred with a Sector Perform at RBC Capital
03/19/21 Piper Sandler
Amneal Pharmaceuticals price target raised to $9 from $7 at Piper Sandler
03/08/21 Goldman Sachs
Amneal Pharmaceuticals upgraded to Buy from Sell at Goldman Sachs
ODT Odonate Therapeutics
$3.48 /

+0.025 (+0.72%)

03/22/21 Goldman Sachs
Odonate Therapeutics price target lowered to $4 from $11 at Goldman Sachs
03/22/21 Jefferies
Odonate Therapeutics downgraded to Hold from Buy at Jefferies
03/22/21 Cowen
Odonate Therapeutics downgraded to Market Perform from Outperform at Cowen
08/24/20 Goldman Sachs
Odonate study met endpoint, but safety questions remain, says Goldman Sachs
RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

06/24/21 SVB Leerink
Arcus Biosciences price target raised to $63 from $53 at SVB Leerink
02/25/21 Barclays
Arcus Biosciences price target raised to $45 from $40 at Barclays
02/25/21 Mizuho
Arcus Biosciences price target raised to $43 from $40 at Mizuho
01/20/21 Citi
Arcus Biosciences price target raised to $51 from $32 at Citi
SIRI Sirius XM
$6.35 /

-0.03 (-0.47%)

05/27/21 Morgan Stanley
Sirius XM shares 'cheap,' Liberty Sirius XM 'really cheap,' says Morgan Stanley
02/03/21 Citi
Tax sharing agreement 'very bullish' for Liberty SiriusXM, says Citi
01/28/21
Fly Intel: Top five analyst downgrades
01/28/21 Credit Suisse
Sirius XM downgraded to Neutral after rally at Credit Suisse
PPG PPG
$165.52 /

-4.77 (-2.80%)

07/01/21 Societe Generale
PPG price target raised to $192 from $168 at Societe Generale
05/21/21 Deutsche Bank
PPG price target raised to $205 from $190 at Deutsche Bank
05/14/21 RBC Capital
PPG price target raised to $193 from $180 at RBC Capital
05/11/21 Goldman Sachs
PPG price target raised to $192 from $187 at Goldman Sachs
STLD Steel Dynamics
$58.06 /

-1.8 (-3.01%)

07/07/21 Credit Suisse
Steel demand booming in the U.S., says Credit Suisse
07/01/21 Deutsche Bank
Steel Dynamics price target raised to $72 from $68 at Deutsche Bank
06/18/21 Deutsche Bank
Steel Dynamics price target raised to $68 from $57 at Deutsche Bank
06/16/21
Fly Intel: Top five analyst initiations
ZION Zions Bancorp
$47.69 /

-1.91 (-3.85%)

07/06/21 Keefe Bruyette
Zions Bancorp assumed with a Market Perform at Keefe Bruyette
05/17/21
Fly Intel: Top five analyst downgrades
05/17/21 Baird
Zions Bancorp downgraded to Underperform from Neutral at Baird
04/20/21 Truist
Zions Bancorp price target raised to $70 from $65 at Truist
JBHT J.B. Hunt
$159.83 /

-5.205 (-3.15%)

07/14/21 Citi
J.B. Hunt price target raised to $205 from $197 at Citi
07/13/21 Wells Fargo
J.B. Hunt price target raised to $203 from $192 at Wells Fargo
06/28/21 Barclays
J.B. Hunt price target raised to $180 from $170 at Barclays
06/21/21 Stifel
J.B. Hunt resumed with a Hold at Stifel
ARDX Ardelyx
$7.70 /

+0.195 (+2.60%)

05/06/21 Piper Sandler
Ardelyx's Q1 'largely quiet,' even with PDUFA delay, says Piper Sandler
04/29/21 Piper Sandler
Piper Sandler keeps Ardelyx rating, price target in spite of PDUFA delay
03/22/21 Wedbush
Ardelyx started with Outperform at Wedbush on tenapanor disruptor potential
03/22/21 Wedbush
Ardelyx initiated with an Outperform at Wedbush
ZION Zions Bancorp
$47.69 /

-1.91 (-3.85%)

STLD Steel Dynamics
$58.06 /

-1.8 (-3.01%)

SIRI Sirius XM
$6.35 /

-0.03 (-0.47%)

RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

PPG PPG
$165.52 /

-4.77 (-2.80%)

ODT Odonate Therapeutics
$3.48 /

+0.025 (+0.72%)

JBHT J.B. Hunt
$159.83 /

-5.205 (-3.15%)

IBM IBM
$138.13 /

-0.79 (-0.57%)

CCK Crown Holdings
$101.33 /

-2.47 (-2.38%)

ARDX Ardelyx
$7.70 /

+0.195 (+2.60%)

AMRX Amneal Pharmaceuticals
$4.32 /

+0.01 (+0.23%)

  • 28
    Aug
STLD Steel Dynamics
$58.06 /

-1.8 (-3.01%)

IBM IBM
$138.13 /

-0.79 (-0.57%)

CCK Crown Holdings
$101.33 /

-2.47 (-2.38%)

STLD Steel Dynamics
$58.06 /

-1.8 (-3.01%)

SIRI Sirius XM
$6.35 /

-0.03 (-0.47%)

RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

PPG PPG
$165.52 /

-4.77 (-2.80%)

ODT Odonate Therapeutics
$3.48 /

+0.025 (+0.72%)

JBHT J.B. Hunt
$159.83 /

-5.205 (-3.15%)

IBM IBM
$138.13 /

-0.79 (-0.57%)

CCK Crown Holdings
$101.33 /

-2.47 (-2.38%)

ARDX Ardelyx
$7.70 /

+0.195 (+2.60%)

ZION Zions Bancorp
$47.69 /

-1.91 (-3.85%)

STLD Steel Dynamics
$58.06 /

-1.8 (-3.01%)

SIRI Sirius XM
$6.35 /

-0.03 (-0.47%)

RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

PPG PPG
$165.52 /

-4.77 (-2.80%)

JBHT J.B. Hunt
$159.83 /

-5.205 (-3.15%)

IBM IBM
$138.13 /

-0.79 (-0.57%)

Hot Stocks
Arcus Biosciences chief medical officer Bill Grossman resigns » 16:53
07/19/21
07/19
16:53
07/19/21
16:53
RCUS

Arcus Biosciences

$29.59 /

+0.16 (+0.54%)

, GILD

Gilead

$68.24 /

-0.39 (-0.57%)

In a regulatory 8-K…

In a regulatory 8-K filing, Arcus Biosciences (RCUS) "announced that Bill Grossman M.D., Ph.D., will transition out of his role as chief medical officer at Arcus Biosciences and into a role at Gilead Sciences (GILD) as senior vice president of oncology clinical research to oversee Gilead's clinical-stage oncology portfolio. This will include leading Gilead's efforts in the company's alliance with Arcus to co-develop and co-commercialize Arcus's portfolio of investigational cancer medicines. Kartik Krishnan, M.D., Ph.D., senior vice president, clinical development at Arcus, will assume full leadership of the Arcus clinical development program and continue to work closely with Grossman at Gilead. The transition will be effective July 26, 2021."

ShowHide Related Items >><<
RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

GILD Gilead
$68.24 /

-0.39 (-0.57%)

RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

06/24/21 SVB Leerink
Arcus Biosciences price target raised to $63 from $53 at SVB Leerink
02/25/21 Barclays
Arcus Biosciences price target raised to $45 from $40 at Barclays
02/25/21 Mizuho
Arcus Biosciences price target raised to $43 from $40 at Mizuho
01/20/21 Citi
Arcus Biosciences price target raised to $51 from $32 at Citi
GILD Gilead
$68.24 /

-0.39 (-0.57%)

06/29/21 Jefferies
Gilead data should move Yescarta up to second line in DLBCL, says Jefferies
06/16/21 Roth Capital
JTX-1811 IND-clearance further validates Jounce platform, says Roth Capital
06/15/21 Piper Sandler
Jounce Therapeutics receives $25M milestone from Gilead, says Piper Sandler
04/01/21
Fly Intel: Top five analyst upgrades
RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

GILD Gilead
$68.24 /

-0.39 (-0.57%)

GILD Gilead
$68.24 /

-0.39 (-0.57%)

RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

GILD Gilead
$68.24 /

-0.39 (-0.57%)

RCUS Arcus Biosciences
$29.59 /

+0.16 (+0.54%)

GILD Gilead
$68.24 /

-0.39 (-0.57%)

Upgrade
Fly Intel: Top five analyst upgrades » 09:58
07/19/21
07/19
09:58
07/19/21
09:58
AA

Alcoa

$31.61 /

-1.32 (-4.01%)

, QCOM

Qualcomm

$138.11 /

-1.6 (-1.15%)

, KBH

KB Home

$38.55 /

-0.35 (-0.90%)

, CSR

Centerspace

$86.58 /

-0.12 (-0.14%)

, CYBR

CyberArk

$130.95 /

-2.63 (-1.97%)

Catch up on today's…

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Alcoa (AA) upgraded to Conviction Buy from Buy at Goldman Sachs with analyst Emily Chieng saying Alcoa has "significant leverage to a positive commodity price outlook," where every 10% increase in aluminum prices corresponds to a 20% increase in EBITDA. 2. Qualcomm (QCOM) upgraded to Neutral from Sell at Goldman Sachs with analyst Rod Hall believing Qualcomm is "poised to benefit from multiple tailwinds" in the second half of 2021, including an earlier iPhone launch and improving supply situation. 3. KB Home (KBH) upgraded to Buy from Neutral at Seaport Global with analyst Mark Weintraub saying the company's "improved competitive position," helped by de-leveraging and work through of previously de-activated communities, has enhanced its return profile. 4. Centerspace (CSR) upgraded to Outperform from Market Perform at Raymond James with analyst Buck Horne saying the upgrade reflects the "robust" rent growth recovery currently taking hold across Centerspace's core markets of Minneapolis and Denver, as well as continuing strength in its Midwestern secondary markets. 5. CyberArk (CYBR) upgraded to Buy from Neutral at Colliers with analyst Catharine Trebnick saying the stock is "underappreciated" as CyberArk navigates "lumpy results" due to its SaaS transition. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

ShowHide Related Items >><<
QCOM Qualcomm
$138.11 /

-1.6 (-1.15%)

KBH KB Home
$38.55 /

-0.35 (-0.90%)

CSR Centerspace
$86.58 /

-0.12 (-0.14%)

AA Alcoa
$31.61 /

-1.32 (-4.01%)

AA Alcoa
$31.61 /

-1.32 (-4.01%)

07/18/21 Goldman Sachs
Alcoa upgraded to Conviction Buy from Buy at Goldman Sachs
07/16/21
Fly Intel: Top five analyst upgrades
07/16/21 Citi
Alcoa upgraded to Buy from Neutral at Citi
07/01/21 Jefferies
Alcoa price target raised to $40 from $35.50 at Jefferies
QCOM Qualcomm
$138.11 /

-1.6 (-1.15%)

07/19/21 Goldman Sachs
Qualcomm upgraded to Neutral from Sell at Goldman Sachs
07/08/21 Needham
Lantronix initiated with a Buy at Needham
06/29/21 KGI Securities
Qualcomm initiated with an Outperform at KGI Securities
06/08/21 JPMorgan
Qualcomm shares offer 30% upside potential, says JPMorgan
KBH KB Home
$38.55 /

-0.35 (-0.90%)

07/19/21 Seaport Global
KB Home upgraded to Buy from Neutral at Seaport Global
06/24/21 RBC Capital
KB Home price target raised to $47 from $46 at RBC Capital
06/15/21 Wedbush
Wedbush sees pullback in KB Home shares as buying opportunity
04/15/21 Wells Fargo
KB Home initiated with an Overweight at Wells Fargo
CSR Centerspace
$86.58 /

-0.12 (-0.14%)

07/19/21 Raymond James
Centerspace upgraded to Outperform from Market Perform at Raymond James
07/19/21 Raymond James
Centerspace upgraded to Outperform from Market Perform at Raymond James
06/03/21 BTIG
Centerspace upgraded to Buy from Neutral at BTIG
06/03/21 BTIG
Centerspace upgraded to Buy from Neutral at BTIG
CYBR CyberArk
$130.95 /

-2.63 (-1.97%)

07/19/21 Colliers
Colliers upgrades 'underappreciated' CyberArk to Buy
07/19/21 Colliers
CyberArk upgraded to Buy from Neutral at Colliers
05/24/21 Stifel
CyberArk resumed with a Buy at Stifel
05/06/21 DA Davidson
CyberArk price target lowered to $175 from $200 at DA Davidson
QCOM Qualcomm
$138.11 /

-1.6 (-1.15%)

KBH KB Home
$38.55 /

-0.35 (-0.90%)

CYBR CyberArk
$130.95 /

-2.63 (-1.97%)

CSR Centerspace
$86.58 /

-0.12 (-0.14%)

AA Alcoa
$31.61 /

-1.32 (-4.01%)

QCOM Qualcomm
$138.11 /

-1.6 (-1.15%)

KBH KB Home
$38.55 /

-0.35 (-0.90%)

AA Alcoa
$31.61 /

-1.32 (-4.01%)

QCOM Qualcomm
$138.11 /

-1.6 (-1.15%)

KBH KB Home
$38.55 /

-0.35 (-0.90%)

AA Alcoa
$31.61 /

-1.32 (-4.01%)

QCOM Qualcomm
$138.11 /

-1.6 (-1.15%)

KBH KB Home
$38.55 /

-0.35 (-0.90%)

AA Alcoa
$31.61 /

-1.32 (-4.01%)

Upgrade
KB Home upgraded to Buy from Neutral at Seaport Global » 06:45
07/19/21
07/19
06:45
07/19/21
06:45
KBH

KB Home

$38.91 /

-0.39 (-0.99%)

Seaport Global analyst…

Seaport Global analyst Mark Weintraub upgraded KB Home to Buy from Neutral with a $50 price target. The company's "improved competitive position," helped by de-leveraging and work through of previously de-activated communities, has enhanced its return profile, Weintraub tells investors in a research note. While KB's order growth will decelerate as the comps get much tougher, its fundamental demographics "look good for the next several years," says the analyst. He believes the share downside will be "cushioned" by the company's book value and cash generation.

ShowHide Related Items >><<
KBH KB Home
$38.91 /

-0.39 (-0.99%)

KBH KB Home
$38.91 /

-0.39 (-0.99%)

06/24/21 RBC Capital
KB Home price target raised to $47 from $46 at RBC Capital
06/15/21 Wedbush
Wedbush sees pullback in KB Home shares as buying opportunity
04/15/21 Wells Fargo
KB Home initiated with an Overweight at Wells Fargo
KBH KB Home
$38.91 /

-0.39 (-0.99%)

KBH KB Home
$38.91 /

-0.39 (-0.99%)

KBH KB Home
$38.91 /

-0.39 (-0.99%)

KBH KB Home
$38.91 /

-0.39 (-0.99%)

Periodicals
Impossible Foods to launch plant-based chicken nugget this fall, Bloomberg says » 14:43
07/16/21
07/16
14:43
07/16/21
14:43
BYND

Beyond Meat

$126.55 /

-2.52 (-1.95%)

Impossible Foods intends…

Impossible Foods intends to debut a plant-based chicken nugget this fall, challenging rival Beyond Meat in the market for imitation chicken, Bloomberg's Deena Shanker reports. The new food category will be unveiled to potential customers at a trade show next week, and uses textured soy protein and sunflower oil to replicate the feeling of eating chicken nuggets, Shanker says, noting that the Impossible nugget doesn't include heme. Reference Link

ShowHide Related Items >><<
BYND Beyond Meat
$126.55 /

-2.52 (-1.95%)

BYND Beyond Meat
$126.55 /

-2.52 (-1.95%)

06/23/21 JPMorgan
Beyond Meat breakfast sandwich discontinued at Dunkin', says JPMorgan
05/24/21
Fly Intel: Top five analyst upgrades
05/24/21 Bernstein
Beyond Meat upgraded to Outperform from Underperform at Bernstein
05/11/21 Barclays
Beyond Meat price target lowered to $90 from $100 at Barclays
BYND Beyond Meat
$126.55 /

-2.52 (-1.95%)

BYND Beyond Meat
$126.55 /

-2.52 (-1.95%)

BYND Beyond Meat
$126.55 /

-2.52 (-1.95%)

BYND Beyond Meat
$126.55 /

-2.52 (-1.95%)

Conference/Events
Arcus Biosciences participates in a conference call with Cantor Fitzgerald » 10:25
07/15/21
07/15
10:25
07/15/21
10:25
RCUS

Arcus Biosciences

$27.04 /

-1.57 (-5.49%)

Biotech Analyst Young…

Biotech Analyst Young holds a conference call with CEO Rosen and President Jaen who will provide an overview of the Company pipeline including anti-TIGIT, dual A2a/A2b adenosine receptor antagonist, and CD73 inhibitor programs on July 15 at 11 am hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$27.04 /

-1.57 (-5.49%)

RCUS Arcus Biosciences
$27.04 /

-1.57 (-5.49%)

06/24/21 SVB Leerink
Arcus Biosciences price target raised to $63 from $53 at SVB Leerink
02/25/21 Barclays
Arcus Biosciences price target raised to $45 from $40 at Barclays
02/25/21 Mizuho
Arcus Biosciences price target raised to $43 from $40 at Mizuho
01/20/21 Citi
Arcus Biosciences price target raised to $51 from $32 at Citi
RCUS Arcus Biosciences
$27.04 /

-1.57 (-5.49%)

RCUS Arcus Biosciences
$27.04 /

-1.57 (-5.49%)

RCUS Arcus Biosciences
$27.04 /

-1.57 (-5.49%)

Hot Stocks
Beyond Meat launches e-commerce store in China via JD.com » 10:13
07/15/21
07/15
10:13
07/15/21
10:13
BYND

Beyond Meat

$130.00 /

+2.105 (+1.65%)

, JD

JD.com

$77.86 /

+2.41 (+3.19%)

Beyond Meat (BYND)…

Beyond Meat (BYND) announced the launch of a new ecommerce site on China's JD.com (JD). "This new online store is Beyond Meat's first e-commerce channel in China, and will offer a variety of its delicious and nutritious plant-based products like Beyond Beef, the Beyond Burger and Beyond Pork in Beijing, Shanghai, Guangzhou and Shenzhen, with plans to expand to 300 cities in the country. The opening of the store also marks the first time that consumers can directly purchase Beyond Pork, a savory and sumptuous product that was created exclusively for the Chinese market," the company said in a statement. Shares of Beyond Meat are up 3% to $131.98 in morning trading.

ShowHide Related Items >><<
JD JD.com
$77.86 /

+2.41 (+3.19%)

BYND Beyond Meat
$130.00 /

+2.105 (+1.65%)

BYND Beyond Meat
$130.00 /

+2.105 (+1.65%)

06/23/21 JPMorgan
Beyond Meat breakfast sandwich discontinued at Dunkin', says JPMorgan
05/24/21
Fly Intel: Top five analyst upgrades
05/24/21 Bernstein
Beyond Meat upgraded to Outperform from Underperform at Bernstein
05/11/21 Barclays
Beyond Meat price target lowered to $90 from $100 at Barclays
JD JD.com
$77.86 /

+2.41 (+3.19%)

07/13/21 Arete
JD.com price target lowered to $95 from $100 at Arete
07/02/21 Goldman Sachs
JD.com price target raised to $130 from $119 at Goldman Sachs
06/01/21 Spin-Off Research
JD.com initiated with a Buy at Spin-Off Research
05/21/21 Susquehanna
JD.com price target lowered to $80 from $90 at Susquehanna
JD JD.com
$77.86 /

+2.41 (+3.19%)

BYND Beyond Meat
$130.00 /

+2.105 (+1.65%)

JD JD.com
$77.86 /

+2.41 (+3.19%)

BYND Beyond Meat
$130.00 /

+2.105 (+1.65%)

JD JD.com
$77.86 /

+2.41 (+3.19%)

BYND Beyond Meat
$130.00 /

+2.105 (+1.65%)

JD JD.com
$77.86 /

+2.41 (+3.19%)

BYND Beyond Meat
$130.00 /

+2.105 (+1.65%)

Conference/Events
Arcus Biosciences participates in a conference call with Cantor Fitzgerald » 04:55
07/15/21
07/15
04:55
07/15/21
04:55
RCUS

Arcus Biosciences

$28.61 /

+0.19 (+0.67%)

Biotech Analyst Young…

Biotech Analyst Young holds a conference call with CEO Rosen and President Jaen who will provide an overview of the Company pipeline including anti-TIGIT, dual A2a/A2b adenosine receptor antagonist, and CD73 inhibitor programs on July 15 at 11 am hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$28.61 /

+0.19 (+0.67%)

RCUS Arcus Biosciences
$28.61 /

+0.19 (+0.67%)

06/24/21 SVB Leerink
Arcus Biosciences price target raised to $63 from $53 at SVB Leerink
02/25/21 Barclays
Arcus Biosciences price target raised to $45 from $40 at Barclays
02/25/21 Mizuho
Arcus Biosciences price target raised to $43 from $40 at Mizuho
01/20/21 Citi
Arcus Biosciences price target raised to $51 from $32 at Citi
RCUS Arcus Biosciences
$28.61 /

+0.19 (+0.67%)

RCUS Arcus Biosciences
$28.61 /

+0.19 (+0.67%)

RCUS Arcus Biosciences
$28.61 /

+0.19 (+0.67%)

Conference/Events
Arcus Biosciences participates in a conference call with Cantor Fitzgerald » 15:36
07/14/21
07/14
15:36
07/14/21
15:36
RCUS

Arcus Biosciences

$28.81 /

+0.39 (+1.37%)

Biotech Analyst Young…

Biotech Analyst Young holds a conference call with CEO Rosen and President Jaen who will provide an overview of the Company pipeline including anti-TIGIT, dual A2a/A2b adenosine receptor antagonist, and CD73 inhibitor programs on July 15 at 11 am hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$28.81 /

+0.39 (+1.37%)

RCUS Arcus Biosciences
$28.81 /

+0.39 (+1.37%)

06/24/21 SVB Leerink
Arcus Biosciences price target raised to $63 from $53 at SVB Leerink
02/25/21 Barclays
Arcus Biosciences price target raised to $45 from $40 at Barclays
02/25/21 Mizuho
Arcus Biosciences price target raised to $43 from $40 at Mizuho
01/20/21 Citi
Arcus Biosciences price target raised to $51 from $32 at Citi
RCUS Arcus Biosciences
$28.81 /

+0.39 (+1.37%)

RCUS Arcus Biosciences
$28.81 /

+0.39 (+1.37%)

RCUS Arcus Biosciences
$28.81 /

+0.39 (+1.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.